A Quick Guide for GLP-1s Semaglutide, Tirzepatide & Retatrutide
Share
Semaglutide
Uniqueness: Semaglutide is a GLP-1 receptor agonist, primarily targeting the GLP-1 receptor.
Typical Dosing Schedule:
-
Starting dose: 0.25 mg once weekly for 4 weeks
-
Increase to 0.5 mg once weekly for 4 weeks
-
Can be increased up to 2.4 mg once weekly, with each dose maintained for at least 4 weeks
Tirzepatide
Uniqueness: Tirzepatide is a dual agonist, targeting both GLP-1 and GIP receptors, potentially offering broader metabolic benefits.
Typical Dosing Schedule:
-
Starting dose: 2.5 mg once weekly for 4 weeks
-
Increase to 5 mg once weekly for 4 weeks
-
Can be increased by 2.5 mg increments up to a maximum of 15 mg once weekly, with each dose maintained for at least 4 weeks
Retatrutide
Uniqueness: Retatrutide is a triple agonist, targeting GLP-1, GIP, and glucagon receptors, potentially offering the most comprehensive approach to weight loss and metabolic health.
Typical Dosing Schedule:
-
As Retatrutide is still in clinical trials, a standardized dosing schedule hasn't been established
-
In studies, doses ranging from .5mg to 12 mg once weekly have been tested
All three medications are administered via subcutaneous injection once weekly. They work by suppressing appetite, slowing gastric emptying, and improving insulin sensitivity. Tirzepatide and Retatrutide may offer additional benefits due to their multi-receptor targeting unique approach.